The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of CD19 chimeric antigen receptor T-cell (CAR-T) therapy versus autologous stem cell transplantation (ASCT) for high-risk diffuse large B-cell lymphoma (DLBCL) in first relapse.
 
Amar Harry Kelkar
No Relationships to Disclose
 
Edward Robert Scheffer Cliff
No Relationships to Disclose
 
Caron Alyce Jacobson
Honoraria - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Consulting or Advisory Role - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Research Funding - Kite, a Gilead company; Pfizer
 
Gregory A. Abel
No Relationships to Disclose
 
Robert Redd
No Relationships to Disclose
 
Stijntje Dijk
No Relationships to Disclose
 
Eline Krijkamp
No Relationships to Disclose
 
M. G. Myriam Hunink
Other Relationship - Cambridge University Press
(OPTIONAL) Uncompensated Relationships - ESTRO
 
Corey S. Cutler
Stock and Other Ownership Interests - 2Seventy Bio; Actinium Pharmaceuticals; AlloVir; Bluebird Bio; Northwest Biotherapeutics; Verastem
Honoraria - Janssen; Omeros; Pfizer
Consulting or Advisory Role - Bristol Myers Squibb; CareDX; Cimeio; CTI BioPharma Corp; Editas Medicine; Equillium; Incyte; Jazz Pharmaceuticals; Mallinckrodt/Therakos; Sanofi
(OPTIONAL) Uncompensated Relationships - Kadmon